Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G T Budd

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Cancer|February 15, 1992
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinomaR M Bukowski, G Inoshita, P Yalavarthi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I study of WR-2721 and carboplatinG T Budd, R Ganapathi, L Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trialC A Russell, S J Green, J O'Sullivan, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|December 1, 1991
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignanciesR M Bukowski, J S Sergi, G T Budd, et al.
Cancer Research|November 15, 1989
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effectsG T Budd, B Osgood, B Barna, et al.
Cancer|September 26, 1997
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsG T Budd, R Ganapathi, D J Adelstein, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effectsR M Bukowski, S Murthy, D McLain, et al.
Cancer Research|August 15, 1991
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinomaR M Bukowski, W Sharfman, S Murthy, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytesM J Thomassen, J M Antal, M J Connors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group StudyG T Budd, T R Fleming, R M Bukowski, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Cancer|February 15, 1992
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinomaR M Bukowski, G Inoshita, P Yalavarthi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I study of WR-2721 and carboplatinG T Budd, R Ganapathi, L Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trialC A Russell, S J Green, J O'Sullivan, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|December 1, 1991
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignanciesR M Bukowski, J S Sergi, G T Budd, et al.
Cancer Research|November 15, 1989
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effectsG T Budd, B Osgood, B Barna, et al.
Cancer|September 26, 1997
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsG T Budd, R Ganapathi, D J Adelstein, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effectsR M Bukowski, S Murthy, D McLain, et al.
Cancer Research|August 15, 1991
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinomaR M Bukowski, W Sharfman, S Murthy, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytesM J Thomassen, J M Antal, M J Connors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group StudyG T Budd, T R Fleming, R M Bukowski, et al.
Pageof 7